# BIO|MASTER.CSP Study

Study · id `cardio:ct-nct06620237` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06620237](<https://clinicaltrials.gov/study/NCT06620237>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06620237

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 152 participants.

## Technical summary

Registry record NCT06620237. Non-randomized; no masking; primary purpose treatment. Start 2024-10-04 (actual); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 152 participants (planned count; ClinicalTrials.gov record NCT06620237, source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)
- Started: 2024-10-04 (actual) (ClinicalTrials.gov record NCT06620237, source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT06620237, source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06620237, source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)
- Countries: Australia; Belgium; France; Netherlands; New Zealand (ClinicalTrials.gov record NCT06620237, source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06620237-2026-10-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: BIO|MASTER.CSP Study
- Condition: Cardiac Pacing, Artificial
- Condition: Cardiac Pacemaker, Artificial
- Condition: Cardiac Resynchronization Therapy Devices
- Condition: Bradycardia
- Condition: Conduction Disorder
- Condition: Conduction Defect, Cardiac
- Condition: Heart Failure
- Intervention (Device): Implantation of the Solia CSP S pacing lead for LBBAP
- Lead sponsor: Biotronik SE & Co. KG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Bradycardia (`cardio:bradycardia`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Biotronik SE & Co. KG (`cardio:org-biotronik-se-co-kg`)

## Provenance

Content hash: 2233fa13f477b9c59d78dfa51c3192d91080f3082c4f5c88a9b5908765a2e7cd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
